Drug Trial Radar · NCT05735496
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
219
Actual
Start
Mar 9, 2023
Primary completion
Jul 21, 2025
Study completion Jul 2027
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.
Conditions
- Advanced Cancer
Interventions
TQB2102 injectionDrug
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: During the first treatment cycle (21 days).
- Maximum tolerated dose (MTD)Time frame: During the first treatment cycle (21 days).
- The occurrence rate of all adverse events (AEs)Time frame: From date of the first dose until 28 days after last dose or new anti-tumor treatment, whichever came first.
- Dose escalation: recommended phase 2 dose (RP2D)Time frame: Up to 2 years
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital.
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, China
Harbin, Heilongjiang, China
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Fudan University shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Mianyang Central Hospital
Mianyang, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.